z-logo
Premium
Recent insights into NF ‐κ B signalling pathways and the link between inflammation and prostate cancer
Author(s) -
Nguyen Daniel P.,
Li Jinyi,
Yadav Shalini S.,
Tewari Ashutosh K.
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12488
Subject(s) - prostate cancer , cancer research , inflammation , carcinogenesis , nf κb , iκb kinase , relb , signal transduction , prostate , metastasis , myeloid , cancer , nfkb1 , biology , medicine , immunology , microbiology and biotechnology , transcription factor , biochemistry , gene
Inflammation is involved in regulation of cellular events in prostate carcinogenesis through control of the tumour micro‐environment. A variety of bone marrow‐derived cells, including CD 4+ lymphocytes, macrophages and myeloid‐derived suppressor cells, are integral components of the tumour micro‐environment. On activation by inflammatory cytokines, NF ‐κ B complexes are capable of promoting tumour cell survival through anti‐apoptotic signalling in prostate cancer ( PCa ). Positive feedback loops are able to maintain NF ‐κ B activation. NF ‐κ B activation is also associated with the metastatic phenotype and PCa progression to castration‐resistant prostate cancer ( CRPC ). A novel role for inhibitor of NF ‐κ B kinase ( IKK )‐α in NF ‐κ B ‐independent PCa progression to metastasis and CRPC has recently been uncovered, providing a new mechanistic link between inflammation and PCa . Expansion of PCa progenitors by IKK ‐α may be involved in this process. In this review, we offer the latest evidence regarding the role of the NF ‐κ B pathway in PCa and discuss therapeutic attempts to target the NF ‐κ B pathways. We point out the need to further dissect inflammatory pathways in PCa in order to develop appropriate preventive measures and design novel therapeutic strategies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here